Navigation Links
MIT: blood may help us think
Date:10/16/2007

CAMBRIDGE, Mass.--MIT scientists propose that blood may help us think, in addition to its well-known role as the conveyor of fuel and oxygen to brain cells.

We hypothesize that blood actively modulates how neurons process information, explains Christopher Moore, a principle investigator in the McGovern Institute for Brain Research at MIT, in an invited review in the Journal of Neurophysiology. Many lines of evidence suggest that blood does something more interesting than just delivering supplies. If it does modulate how neurons relay signals, that changes how we think the brain works.

According to Moore's Hemo-Neural Hypothesis, blood is not just a physiological support system but actually helps control brain activity. Specifically, localized changes in blood flow affect the activity of nearby neurons, changing how they transmit signals to each other and hence regulating information flow throughout the brain. Ongoing studies in Moore's laboratory support this view, showing that blood flow does modulate individual neurons.

Moore's theory has implications for understanding brain diseases such as Alzheimer's, schizophrenia, multiple sclerosis and epilepsy. Many neurological and psychiatric diseases have associated changes in the vasculature, says Moore, who is also an assistant professor in MIT's Department of Brain and Cognitive Sciences.

Most people assume the symptoms of these diseases are a secondary consequence of damage to the neurons. But we propose that they may also be a causative factor in the disease process, and that insight suggests entirely new treatments. For example, in epilepsy people often have abnormal blood vessels in the brain region where the seizures occur, and the hypothesis suggests this abnormal flow may induce epileptic onset. If so, drugs that affect blood flow may provide an alternative to current therapies.

The hypothesis also has important implications for functional magnetic resonanc
'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Placenta Is A Rich Source Of Blood Stem Cells
2. White blood cell waste disposal system plays critical regulatory role
3. Epstein-Barr virus protein crucial to its role in blood cancers
4. New insight into regulation of blood stem cells
5. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
6. White Blood Cell Waste Disposal System Plays Critical Regulatory Role
7. Mystery Blood Vessel Disorder Implicated In Mini Strokes
8. Nano-bumps could help repair clogged blood vessels
9. First technology to remove prions that cause vCJD from blood launched
10. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
11. Breakthrough isolating embryo-quality stem cells from blood

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...crets of the earth,s history locked in its icy dep...e information on the environments that have been s...Now, a team of researchers from nine institutions ...0 million dollars by the National Science Foundati...lly. These scientists will drill through the West ...
(Date:11/23/2009)... strain of the deadly superbug MRSAan infection-ca...sposes a far greater health threat than previously...ding to a study in the December issue of Emerging...ly picked up in fitness centers, schools, and othe...en of MRSA within hospitals, the report found. , ...
(Date:11/23/2009)...that a common oral bacterium may exacerbate autoim..., "Unique Lipids from a Common Human Bacterium Rep...ncing Autoimmunity," appears in the December 2009 ...Multiple sclerosis (MS), a disease where the immun...s nearly 1 in 700 people in the United States. Pa...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 1OAG Releases Prototype for Pandemic Disease Planning and Management 56336 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 3Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 1Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 2Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 3Making bacteria make useful proteins 13871 1
...essing their children, at least among side-blotche...States. Researchers at the University of Californi...d lizards are able to induce different color patte... "dressing" their progeny in patterns they will we...ence gives her progeny the patterns most likely to...
...n genetic factors and certain adverse events relat...in the July 15th issue of The Journal of Infectiou...tions for predicting adverse events from other liv...ts has been one of the greatest successes of moder...he world is considered by some to be the crowning ...
...finding new drugs to fight MRSA, cancers and other...isation announced that its fungal collection will ...BI houses one of the world’s largest genetic resou...strains, including Fleming’s original penicillin p...ersity of Strathclyde’s Institute for Drug Researc...
Other Biology News:Study shows lizard moms dress their children for success 2Study shows lizard moms dress their children for success 3Study shows lizard moms dress their children for success 4Genetic factors are linked to fever following smallpox vaccination 2Could fungal collection hold the key to new life-saving drugs? 2
(Date:11/24/2009)... The New York investment bank KTA Capital,s cli...d an AU$6.7 mil convertible note private placement...lacement was arranged by KTA Capital as Neuren,s e... New York (PRWEB) November 23, 2009 ...pital, LLC ("KTA Capital") has announced...
(Date:11/24/2009)...IS, Nov. 24 Sigma-Aldric...at the NASDAQ OMX conference on Tuesday, December ...rested parties may listen via live audio broadcast...tor.sig m a a ldrich.com/ . Users can click ...About Sigma-Aldrich: Sigma-Aldrich is a leading ...
(Date:11/24/2009)...TEO, Calif., Nov. 24 Neu... company focused on developing and commercializing...that Anthony DiTonno, President and Chief Executiv...ual Piper Jaffray Health Care Conference, to be he... in New York, New York. ,, Mr. DiTonno and Ste...
(Date:11/24/2009)...ary efficacy endpoint has been met for patients wi...cer, , QUEBEC CITY, Nov. 24 /PRNewswire-First...: AEZ) (the "Company"), a global biopharmaceutical..., today announced positive efficacy data from a Ph...njugate, AEZS-108 (formerly AN-152), in patients w...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...iated a Phase II study of R1507 ...ark, December 20 Genmab A/S,(OMX: GEN) announced ...e II,clinical study of R1507 for the treatment of ...y was created by Genmab under the company,s,agreem...igger a milestone,payment to Genmab of USD 500,000...
... a,drug and diagnostic discovery company, announce... to initiate a Phase 2 clinical trial of its,thera...mer,s disease. EHT,0202 is a compound, with a nove... memory and neuronal loss., This will be the firs...a multi-center, double-blind trial, in which 135 p...
...; Looks to Build Upon 2007 ...scoring its continued commitment,to advancing acce...he Avon,Foundation today announced the 2008 Avon W... in Avon Walk history, the series will expand into...mentum of a record-breaking,2007 Avon Walk season....
Other Biology Technology:Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 4Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3
RABBIT (BABY) COMPLEMENT LYOPHILISED from AbD Serotec
Rabbit Anti-Human ZO-1 Antibody, Unconjugated from Lab Vision
Mouse Anti-Human Myeloid Marker Monoclonal Antibody, Unconjugated, Clone BM-1 from Santa Cruz Biotechnology, Inc.
5x C'GATE STOCK STABILIZING REAGENT from AbD Serotec
Biology Products: